所有图片(1)
别名:
(17α)-17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid γ-lactone, NSC 261713
经验公式（希尔记法）:
C22H28O3
推荐产品
质量水平
检测方案
≥97% (HPLC)
形式
powder
旋光性
[α]/D +17 to +24°, c = 1 in chloroform-d
颜色
white to beige
溶解性
DMSO: 20 mg/mL, clear
储存温度
room temp
SMILES字符串
C[C@@]12C(C=C[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]45OC(CC5)=O)=CC(CC1)=O
InChI
1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1
InChI key
UJVLDDZCTMKXJK-WNHSNXHDSA-N
基因信息
human ... NR3C2(4306)
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
Canrenone is a mineralocorticoid (aldosterone) inhibitor.
Canrenone is a mineralocorticoid (aldosterone) inhibitor. Aldosterone is known to be involved in hypertension, kidney disease, atherosclerosis, and heart failure. Blockade of the aldosterone receptor has been shown to improve cardiovascular function. In congestive heart failure, aldosterone antagonists are used in addition to other drugs for additive diuretic effect, which reduces edema and the cardiac workload.
Canrenone is an active metabolite of spironolactone with potassium-sparing diuretic activity. Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion. It is known to reduce the inflammatory reaction influenced by aldosterone.
Canrenone is an active metabolite of spironolactone with potassium-sparing diuretic activity. Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion. It is known to reduce the inflammatory reaction influenced by aldosterone.
警示用语：
Warning
危险声明
危险分类
Aquatic Chronic 2 - Carc. 2 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Decio Armanini et al.
Expert opinion on pharmacotherapy, 15(7), 909-912 (2014-03-13)
Canrenone is a derivative of spironolactone with lower antiandrogen activity. The drug is used only in few countries and can block all the side effects of aldosterone (ALDO). The drug is effective even in the presence of normal concentrations of
Li-jun Hu et al.
British journal of clinical pharmacology, 75(5), 1202-1212 (2012-10-24)
Aldosterone antagonists (AldoAs) have been used to treat severe chronic heart failure (CHF). There is uncertainty regarding the efficacy of using AldoAs in mild to moderate CHF with New York Heart Association (NYHA) classifications of I to II. This study
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Armanini D, et al.
Expert Opinion on Pharmacotherapy, 15, 909-912 (2014)
Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
StEiMER W E R N E R, et al.
Clinical Chemistry, 48(3), 507-516 (2002)
Giuseppe Derosa et al.
Annals of medicine, 47(1), 47-52 (2014-10-17)
To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. A total of 156 Caucasian patients were treated with placebo or canrenone
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门